Gastrointestinal bleeding in patients admitted to the intensive care unit

Opriță, Ruxandra; Ilie, Mădălina; Șandru, Vasile; BERCEANU, Daniel; Constantinescu, Gabriel

doi:10.31688/abmu.2018.53.4.09

Cited by 3 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NOACs represent an appealing alternative to the antivitamin K oral anticoagulants (25,26). Currently, their indications are expanding (27), with many ongoing studies and promising results (28).…”

Section: Discussionmentioning

confidence: 99%

New oral anticoagulants�‑�possible extension to other indications (Review)

et al. 2020

View full text Add to dashboard Cite

Anticoagulant treatment is necessary in various conditions, with curative or preventive purposes. Until recently, the only oral anticoagulants available have been vitamin K antagonists. To overcome the disadvantages of the antivitamin K oral anticoagulants, new oral anticoagulants (NOACs) have been developed and included in clinical trials. After more than 60 years of using vitamin K antagonists, the introduction of NOACs represent a medical breakthrough, with promising prospects. Due to their promising results and better safety profile, NOACs have become an appealing alternative to vitamin K antagonists in a short period of time. NOACs have been approved for the prevention and treatment of venous thromboembolism and for the prevention of stroke in patients with nonvalvular atrial fibrillation. Starting with postoperative venous thromboprophylaxis after hip replacement surgery, NOACs have been approved also for other clinical situations. Rivaroxaban is the first oral anticoagulant approved to be used in combination with an antiplatelet agent to prevent atherothrombotic events in adults with coronary artery disease and/or peripheral artery disease. However, further investigation is needed to establish which group of patients would benefit most from this medical approach. Furthermore, preliminary studies have shown that NOACs seem to be a reasonable choice of anticoagulation for patients with cancer, but further studies are expected. Contents 1. Introduction 2. NOACs current indications 3. Stable atherosclerotic vascular disease-prevention of major cardiac events 4. New perspectives-reducing the risk of major cardiovascular events 5. New perspectives-NOACs in patients with malignant diseases 6. Conclusions

show abstract

Section: Discussionmentioning

confidence: 99%

New oral anticoagulants�‑�possible extension to other indications (Review)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Further studies are needed to clarify their potential (ZANOLI & al [57]). It is important to reduce the cardiovascular risk in this subgroup of patients, especially in those with renal failure, where the cardiovascular comorbidities and gastrointestinal disorders are frequent (LEBLEBICIOGLU & al [58]; SYDORCHUK & al [59]; OPRITA & al [60]).…”

Section: Therapeutical Agents Used In Ibd and The Cardiovascular Riskmentioning

confidence: 99%

Cardiovascular risk in patients with inflamma-tory bowel diseases: a review

Manea¹,

Marcu²,

Motofei³

et al. 2019

Rom Biotechnol Lett.

View full text Add to dashboard Cite

Patients with inflammatory bowel diseases (IBD) have an increased risk of cardiovascular events (myocardial infarction, cerebrovascular events and death of cardiovascular causes), because of some common pathophysiological mechanisms. Patients with IBD have high levels of cytokines, C-reactive protein and homocysteine, leading to endothelial dysfunction and atherosclerosis. Also, the increased levels of coagulation factors in patients with IBD lead to an increased risk for thromboembolic events. There are numerous studies that sustain the link between IBD and cardiovascular complications.

show abstract

One in four patients with gastrointestinal bleeding develops shock or hemodynamic instability: A systematic review and meta-analysis

Obeidat¹,

Teutsch²,

Rancz³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

The human intestine is a natural environment ecosystem of a complex of diversified and dynamic microorganisms, determined through a process of competition and natural selection during life. Those intestinal microorganisms called microbiota and are involved in a variety of mechanisms of the organism, they interact with the host and therefore are in contact with the organs of the various systems. However, they play a crucial role in maintaining host homeostasis, also influencing its behaviour. Thus, microorganisms perform a series of biological functions important for human well-being. The host provides the microorganisms with the environment and nutrients, simultaneously drawing many benefits such as their contribution to metabolic, trophic, immunological, and other functions. For these reasons it has been reported that its quantitative and qualitative composition can play a protective or harmful role on the host health. Therefore, a dysbiosis can lead to an association of unfavourable factors which lead to a dysregulation of the physiological processes of homeostasis. Thus, it has previously noted that the gut microbiota can participate in the pathogenesis of autoimmune diseases, chronic intestinal inflammation, diabetes mellitus, obesity and atherosclerosis, psychic disorders (e.g., neurological diseases, autism, etc. ) colorectal cancer, and more.

show abstract

Gastrointestinal bleeding in patients admitted to the intensive care unit

Cited by 3 publications

References 19 publications

New oral anticoagulants�‑�possible extension to other indications (Review)

New oral anticoagulants�‑�possible extension to other indications (Review)

Cardiovascular risk in patients with inflamma-tory bowel diseases: a review

One in four patients with gastrointestinal bleeding develops shock or hemodynamic instability: A systematic review and meta-analysis

Contact Info

Product

Resources

About